Biography
The son of a pharmaceuticals distributor, Dilip Shanghvi borrowed $200 from his father to start Sun Pharmaceutical Industries in 1983 to make psychiatric drugs. The company is India's most valuable listed pharma outfit and gets two-thirds of its $6.1 billion annual revenue from overseas markets. He grew Sun through a series of acquisitions, the biggest of which was the 2014 purchase of scandal-tainted rival Ranbaxy Laboratories for $4 billion. Sun Pharma acquired U.S. skin cancer drug maker Checkpoint Therapeutics in May 2025 for $355 million. In February 2025, his son Aalok was appointed as chief operating officer of Sun Pharma.